Citigroup Maintains Buy on Mirum Pharmaceuticals, Raises Price Target to $160

Benzinga Newsdesk www.benzinga.com Positive 84.8%

Neg 0% Neu 0% Pos 84.8%

Citigroup analyst Yigal Nochomovitz maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and raises the price target from $145 to $160.